Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35506446/
doi: 10.1002/jimd.12509. Online ahead of print. 1 Biologie Hématologique, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. 2 Service de Gastro-Entérologie et Hépatologie Pédiatrique, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. 3 Groupe...
Conclusion: Our data shows that SGLT2 inhibitors are an excellent alternative to treat the neutropenia present in G6PC3-deficiency
Management strategies in heart failure with preserved ejection fraction
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075717/
Language: English | German The diagnosis and therapy of heart failure with preserved ejection fraction (HFpEF) remain challenging. Currently, there are ongoing discussions on whether the diagnosis of HFpEF should...
Conclusion: Overall, this review aims to enhance the knowledge on the diagnostic processes and best treatments available for HFpEF patients.
New therapies for the treatment of heart failure with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35524990/
doi: 10.1093/ajhp/zxac129. Online ahead of print. 1 South University School of Pharmacy, Savannah, GA, and St. Joseph's/Candler Health System, Savannah, GA, USA. 2 St. Joseph's/Candler Health System, Savannah, GA, USA....
Conclusion: The PARAGON-HF and EMPEROR-Preserved trials will serve as the foundation for a new era in the treatment of HFpEF.
Healthcare resource utilization and associated costs | CEOR
In Germany, the current estimates of the prevalence of diabetes range between 7.2% (population aged 18 to 79 years) based on health examination surveys of the Robert Koch Institute and...
Conclusion: Although the individual clinical patient profile and physician assessment are paramount in treatment decisions, substantial differences in the economic impact of different antidiabetic therapies should be considered.
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35501824/
Empagliflozin showed some positive effects in 4 cases with better renal function than CKD stage 4. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors...
Conclusion: Empagliflozin showed some positive effects in 4 cases with better renal function than CKD stage 4. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors in a larger group of patients with similar medical conditions.
-
Heart Failure Connect4yrKey Points • Source: BMC Nephrology • Conclusion: “Empagliflozin showed some positive effects in 4 cases with better renal function than CKD [chronic kidney disease] stage 4. Further studies will Show More